The Biden administration says Medicare recipients will save about $1.5 billion on out-of-pocket costs for medications to treat diabetes, heart disease, types of arthritis and other ailments under new prices negotiated with drug companies that will take effect in 2026.The savings range from 79% for Januvia, used to manage diabetes, to 38% for Imbruvica, which is used to treat blood cancers. That is the medication’s cost before any discounts or rebates are applied, but not what the price people actually pay when filling their prescriptions. A look at the drugs and the negotiated prices.Manufacturer: Merck Sharp DohmeConditions: DiabetesNegotiated price: $113 for a 30-day supplyReduction: 79%Manufacturer: Novo NorodiskConditions: DiabetesNegotiated price: $119 for a 30- day supplyReduction: 76%Manufacturer: AstraZeneca AB.Conditions: Diabetes, heart failure and chronic kidney diseaseNegotiated price: $178.50 for a 30-day supplyReduction: 68%Manufacturer: Immunex Corp.Conditions: Rheumatoid arthritis, psoriasis and psoriatic arthritisNegotiated price: $2,355 for a 30-day supplyReduction: 67%Manufacturer: Boehringer IngelheimConditions: Diabetes, heart failure and chronic kidney diseaseNegotiated price: $197 for a 30-day supplyReduction: 66%Manufacturer: Janssen Biotech Inc.Conditions: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitisNegotiated price: $4,695 for a 30-day supplyReduction: 66%Manufacturer: Janssen PharmsConditions: Prevention and treatment of blood clots. Reduction of risk for patients with coronary or peripheral artery diseaseNegotiated price: $197 for a 30-day supplyReduction: 62%Manufacturer: Bristol Myers SquibbConditions: Prevention and treatment of blood clotsNegotiated price: $231 for a 30-day supplyReduction: 56%Manufacturer: Novartis Pharms CorpConditions: Heart failureNegotiated price: $295 for a 30-day supplyReduction: 53%Manufacturer: Pharmacyclics LLCConditions: Blood cancersNegotiated price: $9,319 for a 30-day supplySavings: 38%